Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAN6 hexavalent vaccine in Thai infants and toddlers
NCT04429295Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of DTwP-HepB-Hib-IPV hexavalent vaccine in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by Sanofi. Started Jun 2020; status: completed.
02
Drugs
DTwP-HepB-Hib-IPV hexavalent vaccine
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT04429295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429295.